Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (3286)	9/30/2002 6:52:39 PM
From: Qualified Opinion	Read Replies (2) \| Respond to of 10345

Icebrg, furthermore Elan mentioned prescription growth. It should be verified with Elan. Excerpt from press release: "While the prescriptions for Elan's key US promoted brands continue to grow, product revenues are expected to be approximately $200 million in the third quarter, compared to $375 million in the second quarter of 2002. The reduction in revenues of approximately $175 million is principally attributable to the genericization of Zanaflex ($60 million) and the termination of the arrangements with Autoimmune ($15 million). The remaining reduction is attributable to the elimination of certain product rationalization revenue sources; a change in Elan's discounting strategy; short-term product supply due to manufacturing constraints of third parties; and the asset divestiture program. "